CANO · Cano Health, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $684.43M | - | $788.07M | $689.37M | $704.34M | - | $498.93M | $689.37M | $704.34M | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | $89.11M | - | $80.82M | $99.42M | $96.47M | - | $111.77M | $106.18M | $96.59M | - |
| Total Operating Expenses | $795.54M | - | $1.25B | $1.01B | $906.44M | - | $696.47M | $720.42M | $715.79M | - |
| D&A | $18.37M | - | $26.74M | $27.25M | $27.22M | - | $25.34M | $19.84M | $5.85M | - |
| Operating Income | ($111.11M) | - | ($466.92M) | ($245.63M) | ($39.53M) | - | ($31.45M) | ($31.05M) | ($11.46M) | - |
| Interest Expense | $14.93M | - | $29.65M | $26.72M | $23.50M | - | $16.45M | $13.13M | $10.63M | - |
| Income Tax | $36.0K | - | ($145.0K) | ($1.87M) | $0 | - | ($1.25M) | $809.0K | $1.08M | - |
| Net Income | ($415.71M) | - | ($260.49M) | ($140.75M) | ($28.15M) | - | ($54.23M) | ($5.33M) | $660.0K | - |
| EPS - Basic | ($90.46) | - | ($91.87) | ($0.51) | ($0.12) | - | ($0.23) | ($0.03) | $0.00 | - |
| EPS - Diluted | ($91.10) | - | ($91.87) | ($0.51) | ($0.12) | - | ($0.23) | ($0.03) | $0.00 | - |
Balance Sheet
| Line item | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $177.99M | $75.76M | $41.33M | $27.72M | $44.89M | $27.33M | $24.10M | $47.85M | $113.05M | $163.17M |
| Accounts Receivable | $54.22M | $75.80M | $87.50M | $107.16M | $242.22M | $233.82M | $202.04M | $200.99M | $191.72M | $133.43M |
| Inventory | - | - | - | - | - | - | - | - | - | $1.11M |
| Accounts Payable | - | - | - | - | - | - | - | - | - | - |
| Current Assets | $255.08M | $182.82M | $144.72M | $166.34M | $313.69M | $340.75M | $304.97M | $287.30M | $323.63M | $317.24M |
| Total Assets | $1.05B | $1.01B | $1.21B | $1.71B | $1.94B | $1.93B | $2.20B | $2.14B | $2.17B | $2.14B |
| Current Liabilities | $267.00M | $1.42B | $365.93M | $336.93M | $213.91M | $208.44M | $185.56M | $142.06M | $158.66M | $161.04M |
| Long-term Debt | $0 | $1.23B | $1.14B | $1.10B | $1.09B | $1.02B | $939.60M | $941.21M | $942.82M | $944.43M |
| Total Liabilities | $2.05B | $1.55B | $1.47B | $1.47B | $1.44B | $1.43B | $1.41B | $1.30B | $1.33B | $1.34B |
| Stockholders' Equity | ($882.22M) | ($347.97M) | ($122.10M) | $146.71M | $280.86M | $252.63M | $406.49M | $412.26M | $386.21M | $318.73M |
| Retained Earnings | ($1.30B) | ($880.45M) | ($715.42M) | ($454.94M) | ($314.18M) | ($286.03M) | ($137.66M) | ($83.43M) | ($78.10M) | ($78.76M) |
Cash Flow
| Line item | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($48.83M) | - | - | - | ($29.47M) | - | - | - | ($37.20M) | - |
| Investing Cash Flow | $3.87M | - | - | - | ($9.46M) | - | - | - | ($9.70M) | - |
| Financing Cash Flow | $147.18M | - | - | - | $56.49M | - | - | - | $542.0K | - |
| CapEx | $814.0K | - | - | - | $5.08M | - | - | - | $7.78M | - |
| Free Cash Flow | ($49.64M) | - | - | - | ($34.55M) | - | - | - | ($44.98M) | - |
Ratios
| Metric | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -16.2% | - | -59.2% | -35.6% | -5.6% | - | -6.3% | -4.5% | -1.6% | - |
| EBITDA margin | -13.5% | - | -55.9% | -31.7% | -1.7% | - | -1.2% | -1.6% | -0.8% | - |
| Net margin | -60.7% | - | -33.1% | -20.4% | -4.0% | - | -10.9% | -0.8% | 0.1% | - |
| Free cash flow margin | -7.3% | - | - | - | -4.9% | - | - | - | -6.4% | - |
| FCF / Net income | 0.12 | - | - | - | 1.23 | - | - | - | -68.15 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | 13.0% | - | 10.3% | 14.4% | 13.7% | - | 22.4% | 15.4% | 13.7% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | 62.1% | - |
| Return on assets | -39.8% | - | -21.5% | -8.2% | -1.4% | - | -2.5% | -0.2% | 0.0% | - |
| Return on equity | 47.1% | - | 213.3% | -95.9% | -10.0% | - | -13.3% | -1.3% | 0.2% | - |
| Return on invested capital | - | - | -36.1% | -15.5% | -2.3% | - | -1.8% | -1.8% | -0.4% | - |
| Liquidity | ||||||||||
| Current ratio | 0.96 | 0.13 | 0.40 | 0.49 | 1.47 | 1.63 | 1.64 | 2.02 | 2.04 | 1.97 |
| Quick ratio | 0.96 | 0.13 | 0.40 | 0.49 | 1.47 | 1.63 | 1.64 | 2.02 | 2.04 | 1.96 |
| Cash ratio | 0.67 | 0.05 | 0.11 | 0.08 | 0.21 | 0.13 | 0.13 | 0.34 | 0.71 | 1.01 |
| Leverage | ||||||||||
| Debt / Equity | 0.00 | -3.54 | -9.37 | 7.51 | 3.88 | 4.05 | 2.31 | 2.28 | 2.44 | 2.96 |
| Debt / Assets | 0.00 | 1.22 | 0.94 | 0.65 | 0.56 | 0.53 | 0.43 | 0.44 | 0.43 | 0.44 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -7.4x | - | -15.7x | -9.2x | -1.7x | - | -1.9x | -2.4x | -1.1x | - |
| Equity multiplier | -1.19 | -2.91 | -9.93 | 11.64 | 6.92 | 7.64 | 5.40 | 5.19 | 5.62 | 6.73 |
| Liabilities / Assets | 1.97 | 1.53 | 1.21 | 0.86 | 0.74 | 0.74 | 0.64 | 0.61 | 0.61 | 0.63 |
| Efficiency | ||||||||||
| Asset turnover | 0.65 | - | 0.65 | 0.40 | 0.36 | - | 0.23 | 0.32 | 0.32 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 29d | - | 41d | 57d | 126d | - | 148d | 106d | 99d | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -2.8% | - | 58.0% | 0.0% | 0.0% | - | -5.3% | 75.3% | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -181.1% | - | -1384.9% | -691.1% | -245.1% | - | -226.4% | -133.0% | -335557.8% | - |
| Net income growth (YoY) | -1376.8% | - | -380.4% | -2539.3% | - | - | -270.5% | - | - | - |
| EPS growth (YoY) | -75816.7% | - | -39843.5% | -1600.0% | - | - | -155.6% | 0.0% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -43.7% | - | - | - | 23.2% | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | - | - | -64.4% | -27.3% | -20.7% | 30.9% | 17.1% | 7624.2% | 6274.6% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2023-12-31.
Product / service
$3.14B totalMedicare$2.87B · 91.4%
Product And Service Other$187.14M · 6.0%
Pharmacy$54.03M · 1.7%
Fee For Service$27.70M · 0.9%
Peer comparison
Same SIC group: Services-Offices & Clinics of Doctors of Medicine
Comparing Cano Health against the 5 most active filers in the same SIC group.